Boundless Bio Inc (BOLD) News

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

BBI-355 Phase 1/2 POTENTIATE clinical trial ongoing; initiated targeted therapy combinations in patients with tumors with EGFR or FGFR oncogene...

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative...

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

STARMAP (Study Treating Acquired Resistance: MAPK Amplifications) is a first-in-human, 3-part, Phase 1/2 study of BBI-825 as a single agent and...

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development...

Amended Statement of Ownership (sc 13g/a)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...

Amended Statement of Ownership (sc 13g/a)

  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE...

Amended Statement of Ownership (sc 13g/a)

      UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington...

Statement of Ownership (sc 13g)

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name...

Amended Statement of Ownership (sc 13g/a)

us05070r1041_020420.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the...

Termination of Registration of a Class of Security Under Section 12(b) (15-12b)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549    ...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:January 17,

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:January 17,